BRAF and central nervous system cancer: For example, it was shown that despite a BRAF-amplified glioma harboring IDH1/2 and ATRX mutations, known for a better prognosis, a reduced survival was observed vs. V600E mutation v-Raf murine sarcoma viral oncogene homolog B1 BRAFv600E [64].